At a glance
ClinicalIndex Comparison RecordN/ACompleted· 16 enrolled
Drug / intervention
JUVÉDERM VOLUMA™ XCdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Jowl Improvement With Injectable Fillers: Jawline Injections Alone vs Jawline and Cheek Injections
In Brief
A clinical study evaluating JUVÉDERM VOLUMA™ XC for Jowls. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This is a prospective clinical study to demonstrate a reduction in jowling and laxity of the jawline that can be achieved following facial volume enhancement using JUVÉDERM VOLUMA™ XC (0.3% w/w lidocaine). The secondary measure will be if this can be achieved with Jawline injection only, or if a superior result can be obtained with both cheek and jowl injection.
Study Details
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartSep 2020
Primary CompletionOct 2022
TodayJul 2026
First PostedMay 15, 2020
Enrollment StartSep 25, 2020
Primary CompletionOct 5, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.1 years ago
Interventions
JUVÉDERM VOLUMA™ XCdevice
Injectable gel